{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:06:18Z","timestamp":1794405978228,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"The Natural Science Foundation of Guangdong Province","award":["2021A1515011320"],"award-info":[{"award-number":["2021A1515011320"]}]},{"name":"Major scientific research project of basic and applied basic research in Guangdong Province","award":["B2022151523007"],"award-info":[{"award-number":["B2022151523007"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1136\/ard-2024-225785","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:15:30Z","timestamp":1716383730000},"page":"1304-1314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":245,"title":["BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct04162353","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05474885","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Weijia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M","family":"DeStefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Pinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Deener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Hagag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fugui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-4631","authenticated-orcid":false,"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225785_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2024-225785_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.12932\/AP0272.31.4.2013","article-title":"Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: a comparison using control sera obtained from healthy individuals and patients with multiple medical problems","volume":"31","author":"Wichainun","year":"2013","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1136\/ard-2024-225785_bib3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1136\/ard-2024-225785_bib4","doi-asserted-by":"crossref","first-page":"e000389","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2024-225785_bib5","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/lupus-2017-000239","article-title":"Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments","volume":"4","author":"Touma","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2024-225785_bib6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.42092","article-title":"Expert perspective: an approach to refractory lupus nephritis","volume":"74","author":"Arora","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225785_bib7","first-page":"e17198","article-title":"Secukinumab on refractory lupus nephritis","volume":"13","author":"Costa","year":"2021","journal-title":"Cureus"},{"key":"10.1136\/ard-2024-225785_bib8","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2024-225785_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking Cd19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225785_bib10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-Cd19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225785_bib11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225785_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1189\/jlb.5BT1115-524R","article-title":"At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies","volume":"100","author":"Oluwole","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.1136\/ard-2024-225785_bib13","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment targets in SLE: remission and low disease activity state","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225785_bib14","doi-asserted-by":"crossref","first-page":"100145","DOI":"10.1016\/j.jtauto.2022.100145","article-title":"Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases","volume":"5","author":"Andrade","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1136\/ard-2024-225785_bib15","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-Cd19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1136\/ard-2024-225785_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a Cd19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1136\/ard-2024-225785_bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-Cd5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1136\/ard-2024-225785_bib18","doi-asserted-by":"crossref","first-page":"1141208","DOI":"10.3389\/fimmu.2023.1141208","article-title":"The role of Interleukin-15 in the development and treatment of hematological malignancies","volume":"14","author":"Sindaco","year":"2023","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225785_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and Cd8 T cells, and cytokine production during first-in-human clinical trial of recombinant human Interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ard-2024-225785_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with Nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1B trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ard-2024-225785_bib21","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225785_bib22","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"10.1136\/ard-2024-225785_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced natural killer cells in Cd19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225785_bib24","doi-asserted-by":"crossref","first-page":"997482","DOI":"10.3389\/fimmu.2022.997482","article-title":"Treatment of aggressive T-cell lymphoma\/leukemia with anti-Cd4 CAR T cells","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225785_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/cjn.2019.294","article-title":"Does resetting the immune system fix multiple sclerosis","volume":"47","author":"Bose","year":"2020","journal-title":"Can J Neurol Sci"},{"key":"10.1136\/ard-2024-225785_bib26","first-page":"107","article-title":"Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"64","author":"Arruda","year":"2016","journal-title":"Curr Res Transl Med"},{"key":"10.1136\/ard-2024-225785_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40120-020-00200-9","article-title":"Autologous hematopoietic stem cell transplantation (AHSCT): standard of care for relapsing-remitting multiple sclerosis patients","volume":"9","author":"Bertolotto","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1136\/ard-2024-225785_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa066","article-title":"When should oncologists use the words hope and cure?","volume":"4","author":"Kiely","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1136\/ard-2024-225785_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2024-225785_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1136\/ard-2024-225785_bib31","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.3390\/ijms21113906","article-title":"CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas","volume":"21","author":"Ahmad","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:35:12Z","timestamp":1740548112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0003496724665131"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225785","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ard-2024-225785.supp9","asserted-by":"subject"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}